The Professional Education & Research Institute (PERI) was founded in 2005 and has grown to become a clinical research organisation recognised globally for managing Phase I through Phase IV clinical trials across pharmaceutical, device, and advanced medicine programmes. The company is headquartered in Roanoke, Virginia, United States, and operates as a global CRO with contracted research sites distributed across the United States, including IBC-certified facilities.

PERI operates as a boutique CRO, positioning itself on nimbleness and close sponsor relationships, and works closely with sponsors to manage studies in a cost-effective manner whilst maintaining standards in Good Clinical Practice and human subject protection. Its leadership team is led by Dr Charles Zelen, Founder and President, who brings over 20 years of clinical, academic, and industry experience in extremities, wound care, and biologic development programmes, having served as principal investigator and primary author on numerous wound healing randomised controlled trials.

PERI’s sponsors are drawn from across the globe, including Asia, Europe, Australia, and North America. The company’s site network and established relationships with key opinion leaders support fast trial start-up timelines and efficient patient recruitment across its focus indications.

Key Products and Services

Clinical Trial Management

• Full-service clinical trial management spanning research, clinical monitoring, site selection and start-up, data management, regulatory affairs, and pharmacovigilance
• Phase I through Phase IV trial execution for biologics, drugs, and medical devices
• Trial rescue services for studies requiring operational recovery or course correction
• Post-market programme management

Site Network and Start-Up

• A network of premier clinical research sites throughout the United States with superior patient recruitment capability, enabling streamlined feasibility, site selection, and training to reduce sponsor time and costs
• IBC-certified site access for gene therapy and advanced therapy studies

Scientific and Strategic Development

• Protocol design and scientific advisory services
• Key opinion leader (KOL) collaborations and scientific advisory networks supporting trial design and execution
• Regulatory strategy and submission support

Therapeutic Specialties

• Core indication expertise in lower extremity conditions, including diabetic foot ulcers, venous leg disease, peripheral neuropathy, peripheral vascular disease, and gene therapy — with PERI having participated in over 50 lower extremity studies
• Additional therapeutic experience spanning rare disease, diabetes, peripheral vascular disease, and peripheral neuropathy
• Further indication coverage in CNS, metabolic, endocrine, plastic surgery, and orthopaedic research

Industry Positioning

PERI occupies a defined niche within the CRO landscape as a boutique, indication-specialist organisation rather than a full-service global provider. Its therapeutic depth in wound care and lower extremity disease — supported by an internationally recognised KOL network — differentiates it from larger CROs that lack the same concentration of indication-specific expertise and site relationships in these fields. PERI’s management structure is notable in that its executive team remains involved at both a strategic level and throughout daily operations, providing a degree of sponsor engagement and continuity that distinguishes it from organisations where senior leadership is separated from trial delivery. For sponsors operating in wound care, gene therapy, or rare lower extremity indications, PERI’s combination of established site relationships, KOL access, and boutique responsiveness positions it as a specialist alternative to larger generalist CROs.